Cleave Biosciences' Series A - III Round

Cleave Biosciences raised a round of funding on April 09, 2013. Investors include New Enterprise Associates.

Cleave Biosciences develops drugs that target protein homeostasis systems and improve the treatment of solid tumors and hematologic malignancies. The company's CB-5083 is an oral inhibitor of p97, a c…

Articles about Cleave Biosciences' Series A - III Round: